{"id":935109,"date":"2026-02-09T07:04:43","date_gmt":"2026-02-09T12:04:43","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-introduces-intapharma-a-label-free-platform-for-nanoparticle-characterization-in-mrna-drug-and-gene-therapy-development-and-qc\/"},"modified":"2026-02-09T07:04:43","modified_gmt":"2026-02-09T12:04:43","slug":"bruker-introduces-intapharma-a-label-free-platform-for-nanoparticle-characterization-in-mrna-drug-and-gene-therapy-development-and-qc","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-introduces-intapharma-a-label-free-platform-for-nanoparticle-characterization-in-mrna-drug-and-gene-therapy-development-and-qc\/","title":{"rendered":"Bruker Introduces iNTApharma\u2122, a Label\u2011Free Platform for Nanoparticle Characterization in mRNA Drug and Gene Therapy Development and QC"},"content":{"rendered":"

<\/p>\n

Bruker Introduces iNTApharma<\/i>\u2122, a Label\u2011Free Platform for Nanoparticle Characterization in mRNA Drug and Gene Therapy Development and QC<\/b><\/p>\n

New iNTApharma system enables rapid, native\u2011state size and concentration measurements with single\u2011particle sensitivity for viral, vesicle, and nanoscale bioparticle workflows<\/i><\/b><\/p>\n

BILLERICA, Mass.–(BUSINESS WIRE<\/a>)–Bruker Corporation<\/a> today announced the launch of iNTApharma<\/i>,<\/b> a label\u2011free characterization platform that provides single\u2011particle sensitivity for the quantitative analysis of nanoscale bioparticles in native aqueous media. Introduced at SLAS 2026 in Boston<\/b>, iNTApharma<\/i> delivers size and concentration measurements within minutes, supporting research, therapy development and quality control workflows that require direct, native\u2011state assessment of bio-nanoparticle populations without labeling or chemical modifications.<\/p>\n

This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20260209780837\/en\/<\/a><\/p>\n

\"Bruker\u2019s<\/p>\n

Bruker\u2019s iNTApharma system offers label-free, native characterization of vectors used in gene and cell therapy, and of LNPs used in mRNA drug delivery<\/p>\n<\/div>\n

\nQuantitative characterization of bioparticles under native buffer conditions is increasingly important in areas such as extracellular vesicle (EV) research<\/b>, adenovirus (AdV and AAV) development<\/b>, lentiviral vector analysis<\/b>, and lipid nanoparticle (LNP) formulation<\/b> for nucleic\u2011acid delivery. Native\u2011state nanoparticle tracking analysis (NTA) is becoming a requirement in biopharma quality control (QC)<\/b>, where reliable assessment of particle size distributions, concentration levels, and subpopulations is essential for process consistency. As mRNA drug development, as well as cell and gene therapy development expand at double\u2011digit growth rates, demand is increasing for high\u2011precision, native\u2011state characterization of viral vectors, LNPs, and other nanoscale bioparticles. iNTApharma<\/i> addresses these needs through native-state, unlabeled measurements that support analysis across diverse biological matrices.<\/p>\n

\nOptimized for bioparticles from 50 to 300 nanometers<\/b>, iNTApharma<\/i> provides measurement conditions well\u2011suited for lipid nanoparticles, lentiviral vectors, adenoviruses, and extracellular vesicles. The system enables analysis of heterogeneous samples, including the resolution of subpopulations within mixtures. Its built\u2011in well\u2011plate reader functionality<\/b> supports unattended and automated acquisition of datasets in standard laboratory workflows, without specialized sample preparation steps.<\/p>\n

iNTApharma<\/i> builds on optical measurement approaches developed at the Max-Planck-Institute for the Science of Light<\/b> (MPL) in Erlangen, Germany, which are also used in mass photometry (MP). The platform translates advanced interferometric scattering (iSCAT) detection methods into accessible instrumentation for research, therapy development and QC environments.<\/p>\n

\n\u201cThe technology is based on iSCAT microscopy, which has been used in a wide range of quantitative label\u2011free investigations with single\u2011molecule sensitivity,\u201d said Prof. Vahid Sandoghdar<\/b>, Director at the MPL, Germany. \u201ciNTApharma<\/i> makes these capabilities broadly available and provides researchers with a tool that can deepen our understanding of nanoscale bioparticles.\u201d<\/p>\n

\n\u201cNative\u2011state, quantitative analysis of lipid nanoparticles, lentiviral vectors, and vesicle\u2011scale bioparticles is a growing need across biopharma and translational research,\u201d said J\u00fcrgen Srega, the President of the Bruker CALID Group<\/b>. \u201cWith iNTApharma<\/i>, we are introducing a fundamentally new tool that enables precise nanoparticle and bioparticle characterization for mRNA delivery, EV biology, gene therapy development, and nanoscale formulation science.\u201d<\/p>\n

\nInitial systems will be placed with early\u2011access partners in the first half of 2026 to validate workflows under real\u2011world conditions. Broader commercial availability is planned for H2 of 2026.<\/p>\n

About Bruker Corporation \u2013 Leader of the Post-Genomic Era <\/b>(Nasdaq: BRKR)<\/p>\n

\nBruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker\u2019s high-performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with customers, Bruker is enabling innovation and customer success in post-genomic life science molecular and cell biology, in disease biology and translational research, in specialty diagnostics, in applied and biopharma applications, as well as in industrial and cleantech research and QC, and in next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology, molecular diagnostics and therapeutic drug monitoring. For more information, please visit www.bruker.com<\/a>.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260209780837\/en\/<\/a><\/span><\/p>\n

Media Contact:
\n<\/b>
Natalie Spahl
\n
Head of Global Marketing Bruker Optics
\n
T: +49 173 96 624 25
\n
E: natalie.spahl@bruker.com<\/a><\/p>\n

Investor Contact:
\n<\/b>
Joe Kostka
\n
Director, Investor Relations, Bruker Corporation
\n
T: +1 (978) 313-5800
\n
E: Investor.Relations@bruker.com<\/a><\/p>\n

KEYWORDS:<\/b> Massachusetts United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Technology Research Medical Devices Semiconductor Health Technology Biotechnology Hardware Health Science<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n\n\n\n
Photo<\/b><\/font><\/td>\n<\/tr>\n
\"Photo\"<\/td>\n<\/tr>\n
Bruker\u2019s iNTApharma system offers label-free, native characterization of vectors used in gene and cell therapy, and of LNPs used in mRNA drug delivery<\/font><\/td>\n<\/tr>\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Bruker Introduces iNTApharma\u2122, a Label\u2011Free Platform for Nanoparticle Characterization in mRNA Drug and Gene Therapy Development and QC New iNTApharma system enables rapid, native\u2011state size and concentration measurements with single\u2011particle sensitivity for viral, vesicle, and nanoscale bioparticle workflows BILLERICA, Mass.–(BUSINESS WIRE)–Bruker Corporation today announced the launch of iNTApharma, a label\u2011free characterization platform that provides single\u2011particle sensitivity for the quantitative analysis of nanoscale bioparticles in native aqueous media. Introduced at SLAS 2026 in Boston, iNTApharma delivers size and concentration measurements within minutes, supporting research, therapy development and quality control workflows that require direct, native\u2011state assessment of bio-nanoparticle populations without labeling or chemical modifications. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20260209780837\/en\/ Bruker\u2019s iNTApharma system offers label-free, native characterization … <\/p>\n

Continue reading “Bruker Introduces iNTApharma\u2122, a Label\u2011Free Platform for Nanoparticle Characterization in mRNA Drug and Gene Therapy Development and QC”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-935109","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBruker Introduces iNTApharma\u2122, a Label\u2011Free Platform for Nanoparticle Characterization in mRNA Drug and Gene Therapy Development and QC - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-introduces-intapharma-a-label-free-platform-for-nanoparticle-characterization-in-mrna-drug-and-gene-therapy-development-and-qc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bruker Introduces iNTApharma\u2122, a Label\u2011Free Platform for Nanoparticle Characterization in mRNA Drug and Gene Therapy Development and QC - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Bruker Introduces iNTApharma\u2122, a Label\u2011Free Platform for Nanoparticle Characterization in mRNA Drug and Gene Therapy Development and QC New iNTApharma system enables rapid, native\u2011state size and concentration measurements with single\u2011particle sensitivity for viral, vesicle, and nanoscale bioparticle workflows BILLERICA, Mass.–(BUSINESS WIRE)–Bruker Corporation today announced the launch of iNTApharma, a label\u2011free characterization platform that provides single\u2011particle sensitivity for the quantitative analysis of nanoscale bioparticles in native aqueous media. Introduced at SLAS 2026 in Boston, iNTApharma delivers size and concentration measurements within minutes, supporting research, therapy development and quality control workflows that require direct, native\u2011state assessment of bio-nanoparticle populations without labeling or chemical modifications. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20260209780837\/en\/ Bruker\u2019s iNTApharma system offers label-free, native characterization … Continue reading "Bruker Introduces iNTApharma\u2122, a Label\u2011Free Platform for Nanoparticle Characterization in mRNA Drug and Gene Therapy Development and QC"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-introduces-intapharma-a-label-free-platform-for-nanoparticle-characterization-in-mrna-drug-and-gene-therapy-development-and-qc\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-09T12:04:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260209780837\/en\/2714139\/4\/iNTApharma_2.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bruker-introduces-intapharma-a-label-free-platform-for-nanoparticle-characterization-in-mrna-drug-and-gene-therapy-development-and-qc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bruker-introduces-intapharma-a-label-free-platform-for-nanoparticle-characterization-in-mrna-drug-and-gene-therapy-development-and-qc\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Bruker Introduces iNTApharma\u2122, a Label\u2011Free Platform for Nanoparticle Characterization in mRNA Drug and Gene Therapy Development and QC\",\"datePublished\":\"2026-02-09T12:04:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bruker-introduces-intapharma-a-label-free-platform-for-nanoparticle-characterization-in-mrna-drug-and-gene-therapy-development-and-qc\\\/\"},\"wordCount\":784,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bruker-introduces-intapharma-a-label-free-platform-for-nanoparticle-characterization-in-mrna-drug-and-gene-therapy-development-and-qc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260209780837\\\/en\\\/2714139\\\/4\\\/iNTApharma_2.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bruker-introduces-intapharma-a-label-free-platform-for-nanoparticle-characterization-in-mrna-drug-and-gene-therapy-development-and-qc\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bruker-introduces-intapharma-a-label-free-platform-for-nanoparticle-characterization-in-mrna-drug-and-gene-therapy-development-and-qc\\\/\",\"name\":\"Bruker Introduces iNTApharma\u2122, a Label\u2011Free Platform for Nanoparticle Characterization in mRNA Drug and Gene Therapy Development and QC - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bruker-introduces-intapharma-a-label-free-platform-for-nanoparticle-characterization-in-mrna-drug-and-gene-therapy-development-and-qc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bruker-introduces-intapharma-a-label-free-platform-for-nanoparticle-characterization-in-mrna-drug-and-gene-therapy-development-and-qc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260209780837\\\/en\\\/2714139\\\/4\\\/iNTApharma_2.jpg\",\"datePublished\":\"2026-02-09T12:04:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bruker-introduces-intapharma-a-label-free-platform-for-nanoparticle-characterization-in-mrna-drug-and-gene-therapy-development-and-qc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bruker-introduces-intapharma-a-label-free-platform-for-nanoparticle-characterization-in-mrna-drug-and-gene-therapy-development-and-qc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bruker-introduces-intapharma-a-label-free-platform-for-nanoparticle-characterization-in-mrna-drug-and-gene-therapy-development-and-qc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260209780837\\\/en\\\/2714139\\\/4\\\/iNTApharma_2.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260209780837\\\/en\\\/2714139\\\/4\\\/iNTApharma_2.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bruker-introduces-intapharma-a-label-free-platform-for-nanoparticle-characterization-in-mrna-drug-and-gene-therapy-development-and-qc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bruker Introduces iNTApharma\u2122, a Label\u2011Free Platform for Nanoparticle Characterization in mRNA Drug and Gene Therapy Development and QC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bruker Introduces iNTApharma\u2122, a Label\u2011Free Platform for Nanoparticle Characterization in mRNA Drug and Gene Therapy Development and QC - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-introduces-intapharma-a-label-free-platform-for-nanoparticle-characterization-in-mrna-drug-and-gene-therapy-development-and-qc\/","og_locale":"en_US","og_type":"article","og_title":"Bruker Introduces iNTApharma\u2122, a Label\u2011Free Platform for Nanoparticle Characterization in mRNA Drug and Gene Therapy Development and QC - Market Newsdesk","og_description":"Bruker Introduces iNTApharma\u2122, a Label\u2011Free Platform for Nanoparticle Characterization in mRNA Drug and Gene Therapy Development and QC New iNTApharma system enables rapid, native\u2011state size and concentration measurements with single\u2011particle sensitivity for viral, vesicle, and nanoscale bioparticle workflows BILLERICA, Mass.–(BUSINESS WIRE)–Bruker Corporation today announced the launch of iNTApharma, a label\u2011free characterization platform that provides single\u2011particle sensitivity for the quantitative analysis of nanoscale bioparticles in native aqueous media. Introduced at SLAS 2026 in Boston, iNTApharma delivers size and concentration measurements within minutes, supporting research, therapy development and quality control workflows that require direct, native\u2011state assessment of bio-nanoparticle populations without labeling or chemical modifications. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20260209780837\/en\/ Bruker\u2019s iNTApharma system offers label-free, native characterization … Continue reading \"Bruker Introduces iNTApharma\u2122, a Label\u2011Free Platform for Nanoparticle Characterization in mRNA Drug and Gene Therapy Development and QC\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-introduces-intapharma-a-label-free-platform-for-nanoparticle-characterization-in-mrna-drug-and-gene-therapy-development-and-qc\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-09T12:04:43+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260209780837\/en\/2714139\/4\/iNTApharma_2.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-introduces-intapharma-a-label-free-platform-for-nanoparticle-characterization-in-mrna-drug-and-gene-therapy-development-and-qc\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-introduces-intapharma-a-label-free-platform-for-nanoparticle-characterization-in-mrna-drug-and-gene-therapy-development-and-qc\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Bruker Introduces iNTApharma\u2122, a Label\u2011Free Platform for Nanoparticle Characterization in mRNA Drug and Gene Therapy Development and QC","datePublished":"2026-02-09T12:04:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-introduces-intapharma-a-label-free-platform-for-nanoparticle-characterization-in-mrna-drug-and-gene-therapy-development-and-qc\/"},"wordCount":784,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-introduces-intapharma-a-label-free-platform-for-nanoparticle-characterization-in-mrna-drug-and-gene-therapy-development-and-qc\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260209780837\/en\/2714139\/4\/iNTApharma_2.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-introduces-intapharma-a-label-free-platform-for-nanoparticle-characterization-in-mrna-drug-and-gene-therapy-development-and-qc\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-introduces-intapharma-a-label-free-platform-for-nanoparticle-characterization-in-mrna-drug-and-gene-therapy-development-and-qc\/","name":"Bruker Introduces iNTApharma\u2122, a Label\u2011Free Platform for Nanoparticle Characterization in mRNA Drug and Gene Therapy Development and QC - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-introduces-intapharma-a-label-free-platform-for-nanoparticle-characterization-in-mrna-drug-and-gene-therapy-development-and-qc\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-introduces-intapharma-a-label-free-platform-for-nanoparticle-characterization-in-mrna-drug-and-gene-therapy-development-and-qc\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260209780837\/en\/2714139\/4\/iNTApharma_2.jpg","datePublished":"2026-02-09T12:04:43+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-introduces-intapharma-a-label-free-platform-for-nanoparticle-characterization-in-mrna-drug-and-gene-therapy-development-and-qc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bruker-introduces-intapharma-a-label-free-platform-for-nanoparticle-characterization-in-mrna-drug-and-gene-therapy-development-and-qc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-introduces-intapharma-a-label-free-platform-for-nanoparticle-characterization-in-mrna-drug-and-gene-therapy-development-and-qc\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260209780837\/en\/2714139\/4\/iNTApharma_2.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260209780837\/en\/2714139\/4\/iNTApharma_2.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-introduces-intapharma-a-label-free-platform-for-nanoparticle-characterization-in-mrna-drug-and-gene-therapy-development-and-qc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Bruker Introduces iNTApharma\u2122, a Label\u2011Free Platform for Nanoparticle Characterization in mRNA Drug and Gene Therapy Development and QC"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/935109","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=935109"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/935109\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=935109"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=935109"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=935109"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}